Q3 2024
Released Nov 13, 2024, after the close
10-Q filed Nov 13, 2024, 44 days after period end · 0000868278-24-000014
Q3 2024 · 10-Q
Revenue$1.42M$1.42M −83.1% vs Q3 2023−5.9% vs Q2 2024
Net Income-$6.59M-$6.59M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$0.35-$0.35 N/M vs Q3 2023N/M vs Q2 2024
Gross Profit$215,000−90.8%
Operating Income-$6,480,000N/M
Operating Cash Flowderived-$4,038,000N/M
Free Cash Flowderived-$4,037,000N/M
Margins · derived
Gross margin15.2%−12.6 pt vs Q3 2023
Operating margin-457.6%−380.2 pt vs Q3 2023
Net margin-465.2%−403.7 pt vs Q3 2023
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $1.42M | $8.37M | $24.20M | $9.47M |
| Net Income | -$6.59M | -$5.14M | $968.00K | -$3.98M |
| EPS Diluted | -$0.35 | -$0.30 | $0.06 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ProPhase Labs, Inc. · CIK 868278 · Engraved from SEC EDGAR